Viewing nowCombinationPravapenic Capsule
Pravastatin Sodium 40mg · Fenofibrate 160mg
Prescription medication · Combination
Yooyoung Pharmaceutical Co., Ltd.

MFDS item code 202300635 · Approved 2023.02.21 · Insurance code 648204690
Treatment of mixed dyslipidemia in high-risk adults with coronary artery disease
Monotherapy with 40mg of Pravastatin effectively regulates LDL cholesterol levels in high-risk adult patients with coronary artery disease. It is used for treating complex dyslipidemia, where triglyceride levels remain high and HDL cholesterol levels appear low. Therefore, this medication mainly helps reduce bad cholesterol, lowering the risk of cardiovascular disease.
Measure creatine phosphokinase (CK) levels before administering this drug. If CK levels are significantly elevated from baseline to more than 5 times the upper limit of normal, they should return to baseline within 5~7 days. If they remain more than 5 times the upper limit of normal after 5~7 days, do not administer this drug. Regular monitoring of CK levels during treatment is recommended every 3 months during the first 12 months after starting this drug, and for a longer period if necessary. Advise patients to consult a physician immediately if they experience unexplained muscle pain, tenderness, weakness, or cramps; CK levels should be measured in such cases. If CK levels are markedly elevated (more than 5 times the upper limit of normal), discontinue this drug. It is recommended that AST and ALT levels be measured every 3 months during the first 12 months of treatment with this drug, and monitored for a longer period if necessary. Discontinue this drug if AST or ALT levels remain persistently elevated to more than 3 times the upper limit of normal. It is recommended that creatinine clearance be measured every 3 months during the first 12 months after starting this drug for systematic evaluation, and monitored for a longer period if necessary. Discontinue this drug if creatinine clearance is less than 60 mL/min. Before starting treatment, patients should follow a standard cholesterol-lowering diet and other nonpharmacological measures (such as exercise), and continue these during treatment. The recommended dose is 1 capsule once daily with the evening meal. This drug must be taken with food because taking it on an empty stomach reduces absorption. Serum lipid levels should be closely monitored in response to treatment. Serum lipid levels generally decrease rapidly after starting this drug. Discontinue treatment if lipid levels are not adequately controlled within 3 months of starting treatment. Elderly patients (65 years and older): Renal function should be assessed before starting treatment. Use caution because the safety of this drug has not been established in patients 75 years and older. Patients with renal impairment: No dose adjustment is necessary when administering this drug to patients with mild renal impairment. However, do not administer it to patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min). Patients with hepatic impairment: No dose adjustment is necessary when administering this drug to patients with mild hepatic impairment. However, administration is not recommended in patients with moderate hepatic impairment and should not be given to patients with severe hepatic impairment.
This medication may cause symptoms such as muscle pain or weakness, so muscle-related tests must be performed before administration. Special caution should be taken for those aged 70 and above, or those with kidney, liver, thyroid issues, or high alcohol consumption, as the risk of muscle toxicity is higher. If muscle pain or weakness occurs, consult a doctor immediately and get tested; in severe cases, discontinuation may be necessary. This medication can affect liver function; therefore, regular liver function tests should be conducted, and if liver enzyme levels rise significantly, the medication should be discontinued. If kidney function is poor, do not take this medication, and kidney function should be regularly monitored during treatment. Pregnant women, women who could become pregnant, and breastfeeding women should not use this medication. Safety has not been established for children under 18 years old; therefore, this medication is not used in this age group. During treatment, watch for sudden shortness of breath, skin rashes, severe muscle pain, or any allergic or serious side effects, and visit a hospital if any unusual symptoms occur. This drug may interact with other medications, so inform your doctor or pharmacist of any other medications you are taking. It is recommended to take it with food, and combining it with dietary changes and exercise helps enhance treatment effectiveness. Elderly patients should carefully monitor kidney function, especially for those over 75 years old who should use it more cautiously. In case of overdose, seek medical attention immediately.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is advisable to keep the storage temperature between 1°C to 30°C at room temperature. This helps maintain the medication's effectiveness for a longer duration.
A hard capsule containing a pale yellow, semi-solid, round coated tablet with a dark green upper part and light green lower part.
30 capsules/bottle, 90 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPravastatin Sodium 40mg · Fenofibrate 160mg
Prescription medication · Combination
Yooyoung Pharmaceutical Co., Ltd.
Pravastatin Sodium · Fenofibrate
Prescription medication · Combination
Youyoung Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.